MASH as a Histological Target: Disease Biology and Regulatory Framework

MASH is a multifactorial hepatic disease defined by the convergence of hepatic lipid accumulation (steatosis), hepatocellular inflammation and ballooning, and progressive fibrosis that can culminate in cirrhosis and hepatocellular carcinoma. The primary cellular driver of fibrosis is the activated hepatic stellate cell (HSC), which is the principal source of extracellular matrix deposition in MASH-related fibrosis — a finding established across multiple retrieved sources including work by Friedman SL et al. (2022). HSC activation is driven by lipotoxicity, oxidative stress, and pro-inflammatory cytokines including TNF-alpha, IL-6, and TGF-beta1.

The regulatory measurement framework for MASH histology is anchored to two constructs: the NAFLD Activity Score (NAS) — which decomposes into steatosis, lobular inflammation, and hepatocellular ballooning sub-scores — and the Clinical Research Network (CRN) fibrosis staging system (F0–F4). According to Ratziu V et al. (2023), both the FDA and the European Medicines Agency require a dual primary endpoint approach in Phase III MASH trials: MASH resolution without worsening of fibrosis, AND improvement in fibrosis of at least one CRN stage without worsening of MASH. These are treated as semi-independent pathological processes requiring separate demonstration of benefit.

The FDA approval of resmetirom (Rezdiffra) for MASH with fibrosis stages F2–F3 established histological improvement as a viable regulatory path, as described by Loomba R et al. (2024). This precedent directly informs the ESSENCE trial design for semaglutide, particularly the dual primary endpoint structure and the patient population selection of F2–F3 fibrosis. Liver biopsy remains the regulatory gold standard for histological assessment, though non-invasive tests including liver stiffness measurement by elastography, ELF score, FIB-4, and PRO-C3 are increasingly integrated as companion diagnostics and surrogate monitoring tools, per Sanyal AJ et al. (2023).

From Phase II Signal to Phase III Ambition: The Path to ESSENCE

The ESSENCE trial is a Phase III randomized, double-blind, placebo-controlled trial evaluating subcutaneous semaglutide 2.4 mg once weekly in patients with MASH and liver fibrosis stages F2–F3, with primary histological endpoints assessed at Part 1 (week 72). The dose selection and trial design were directly shaped by the limitations of the Phase II NASH programme.

The Phase II NASH trial, reported by Newsome PN et al. (2021) in 320 patients with biopsy-confirmed NASH, showed MASH resolution in 40% of patients in the highest dose group (0.4 mg) versus 17% in placebo — a clinically meaningful separation. However, no significant improvement in fibrosis stages was observed at the Phase II dose. This absence of fibrosis benefit at 0.4 mg, combined with the dose-dependent weight loss profile of semaglutide, motivated the step-up to the 2.4 mg dose used in the STEP obesity programme for ESSENCE.

“Weight loss of 10% or more of body weight is strongly associated with MASH resolution, while weight loss of 5% or more correlates with fibrosis improvement — and semaglutide 2.4 mg produces mean weight loss of 15–17% in obesity trials.”

The quantitative rationale for the dose escalation is provided by Harrison SA et al. (2023) in a meta-analysis establishing weight loss thresholds for histological benefit: weight loss of at least 10% of body weight is strongly associated with MASH resolution, while weight loss of at least 5% correlates with fibrosis improvement. Because semaglutide 2.4 mg produces mean weight loss of 15–17% in obesity trial settings, the mechanistic basis for expecting histological benefit — including fibrosis regression — at the ESSENCE dose is quantitatively grounded.

Interim signals from the ESSENCE programme, described by Sanyal AJ and Newsome PN et al. (2024), indicate significant reductions in liver stiffness measured by transient elastography, ELF score, and serum ALT and AST in semaglutide-treated patients at interim timepoints — consistent with anti-inflammatory and anti-fibrotic effects preceding the primary histological readout at week 72. These non-invasive test improvements provide early mechanistic validation but do not substitute for the biopsy-based dual primary endpoint.

How GLP-1 Receptor Agonism Acts on the Liver — and Why Indirect Mechanisms Matter

GLP-1 receptor expression in human liver tissue is far more restricted than in pancreatic beta cells, and this distinction has direct implications for understanding how semaglutide produces hepatic benefit. Single-cell RNA sequencing and immunohistochemistry data reported by Ahren B et al. (2022) demonstrate that GLP-1R expression is detectable in liver sinusoidal endothelial cells and portal fibroblasts, but is very low in hepatocytes — the cells most directly involved in steatosis and lipotoxicity. This means that the dominant hepatic effects of semaglutide are predominantly indirect rather than the result of direct hepatocellular GLP-1R signalling.

The indirect mechanisms described across retrieved sources operate through several complementary pathways. Weight loss and improved systemic insulin sensitivity reduce the flux of free fatty acids and glucose into the liver, directly attenuating hepatic steatosis. Drucker DJ (2022) additionally describes modulation of gut microbiome composition and bile acid metabolism as contributing hepatic effects of GLP-1 receptor agonism. At the cellular level, reduced lipotoxicity and oxidative stress lower the activation signals reaching HSCs, thereby attenuating TGF-beta1-driven fibrogenesis and extracellular matrix deposition — the mechanism described by Friedman SL et al. (2022).

A critical unresolved question in the retrieved literature is whether GLP-1R is directly expressed on HSCs. If confirmed, direct GLP-1R signalling on HSCs could contribute to anti-fibrotic benefit independently of weight loss — a distinction with significant implications for the magnitude of fibrosis regression achievable with semaglutide monotherapy versus combination strategies. The patent filing from Novo Nordisk (WO2023099688A1) claims that metabolic improvement mediated by GLP-1R agonism translates to histological improvement independent of weight loss magnitude, though the mechanistic basis for this weight-loss-independent effect requires further elucidation from the ESSENCE biopsy data.

A network meta-analysis by Zhu L et al. (2023) ranked GLP-1 receptor agonists by efficacy in NAFLD/NASH and found semaglutide demonstrated superior reductions in hepatic steatosis (measured by MRI-PDFF), liver enzymes, and body weight compared to liraglutide and dulaglutide, underscoring the dose-dependent nature of GLP-1R agonism in liver disease and supporting the rationale for the higher 2.4 mg dose in ESSENCE. According to WHO estimates, MASH affects a substantial proportion of the global adult population with metabolic risk factors, making the development of effective pharmacological therapies a global public health priority.

The Competitive Landscape: Tirzepatide, Resmetirom, and the Incretin Race in MASH

The MASH treatment landscape has shifted substantially with the FDA approval of resmetirom (Rezdiffra) for fibrosis stages F2–F3, which established a regulatory precedent that now shapes how all subsequent MASH programmes — including ESSENCE — are designed and evaluated. Resmetirom’s approval validated the dual primary endpoint structure and the F2–F3 patient population as the regulatory pathway, as described by Loomba R et al. (2024).

Within the GLP-1-based competitive space, the most significant challenge to ESSENCE comes from tirzepatide’s SYNERGY-NASH programme. Loomba R et al. (2024) describe tirzepatide’s dual GIP/GLP-1 receptor agonism as offering potential additional benefits over selective GLP-1R agonists in MASH, including superior weight loss and differential hepatic metabolic effects. The convergence of multiple incretin-based therapies on the MASH indication represents a paradigm shift in hepatology, as the field transitions from a landscape with no approved pharmacotherapy for MASH to one with potentially multiple mechanistically distinct options within a short timeframe.

A meta-analysis by Mantovani A et al. (2023) confirmed that GLP-1 receptor agonists including semaglutide and liraglutide significantly reduced hepatic steatosis, liver enzymes, and body weight in patients with NAFLD/NASH across randomised controlled trials. The limited data on fibrosis regression available at the time of that analysis formed the core rationale for larger Phase III investigations such as ESSENCE. Cardiovascular risk reduction is an additional competitive differentiator for semaglutide: Targher G et al. (2023) describe that MASH patients carry elevated cardiovascular risk independent of traditional metabolic risk factors, and semaglutide has demonstrated cardiovascular benefit in the SELECT trial (obesity) and SUSTAIN-6 (type 2 diabetes), creating a potential dual hepatic-cardiovascular value proposition that distinguishes it from liver-specific mechanisms like THRbeta agonism. According to data published by NIH, cardiovascular disease remains the leading cause of death in patients with advanced MASH, further reinforcing this differentiation.

Patent Signals: Novo Nordisk’s Combination IP Positions Beyond GLP-1R Monotherapy

Novo Nordisk’s patent filings in the MASH space extend substantially beyond semaglutide monotherapy, signalling a multi-combination pipeline that anticipates the limitations of single-agent GLP-1R agonism — particularly for fibrosis regression, where the indirect mechanism may be insufficient for patients with advanced fibrosis or those who do not achieve adequate weight loss.

Semaglutide + THRbeta Agonist (WO2024052452A1)

The most strategically significant combination filing, disclosed in WO2024052452A1 (Novo Nordisk A/S, 2024), covers semaglutide combined with a thyroid hormone receptor beta agonist — referencing resmetirom-class mechanisms — for the treatment of MASH and hepatic fibrosis. The rationale is mechanistic complementarity: GLP-1R agonism provides systemic metabolic improvement and weight reduction, while THRbeta agonism provides direct hepatic lipid metabolism benefits and anti-fibrotic effects. Given resmetirom’s FDA approval, this combination represents a clinically validated mechanistic pairing. According to EMA guidance on combination therapies in liver disease, demonstrating additive or synergistic histological benefit over individual components is the regulatory expectation for any combination programme.

Semaglutide + ACC Inhibitor (WO2024028461A1)

A second combination patent from Novo Nordisk (WO2024028461A1, 2024) discloses the combination of semaglutide with an acetyl-CoA carboxylase (ACC) inhibitor targeting de novo lipogenesis directly in hepatocytes. Preclinical data cited in the patent demonstrate additive reductions in hepatic triglycerides and fibrosis markers when semaglutide is combined with ACC inhibition. This combination targets the upstream lipogenic pathway that feeds hepatic steatosis independently of dietary fat intake — a mechanism that is not directly addressed by GLP-1R agonism alone, which primarily reduces hepatic fat influx through weight loss and insulin sensitisation.

Patient Stratification and Non-Invasive Monitoring IP

Novo Nordisk has also filed patents covering patient selection algorithms (US20240108674A1, 2024) and non-invasive monitoring methods (US20240082347A1, 2024) for semaglutide treatment in MASH. The patient selection patent claims diagnostic algorithms based on BMI, hepatic fat fraction, FIB-4 score, liver stiffness, and NASH activity score. The monitoring patent claims specific NIT thresholds as surrogate markers of histological response, including MRI-PDFF for hepatic fat quantification and transient elastography for liver stiffness. These filings indicate that Novo Nordisk is building an integrated precision medicine framework around semaglutide in MASH — not simply seeking a broad indication but positioning for stratified patient populations and response-guided treatment algorithms.

Third-party combination strategies in retrieved patent data include Gilead Sciences’ FXR agonist combination (US20230233631A1, 2023) and AstraZeneca’s GLP-1/SGLT2 inhibitor combination (US20230372434A1, 2023). The FXR agonist approach targets bile acid-regulated nuclear receptor signalling to provide direct hepatic anti-inflammatory and anti-fibrotic effects distinct from GLP-1R-mediated metabolic improvement, while the SGLT2 inhibitor combination addresses complementary hepatic lipid, glucose, and inflammatory pathways. Both are at preclinical or IP-filing stage based on retrieved data. The breadth of combination patent activity across multiple assignees signals that the MASH field broadly anticipates that monotherapy — whether GLP-1R, THRbeta, or FXR agonism — will be insufficient for the full spectrum of MASH severity, and that combination regimens will define the next therapeutic generation.

The broader IP landscape, as surveyed through retrieved results, reflects a field in rapid transition. The WIPO patent database shows accelerating filings in MASH-related combination therapies from 2022 onwards, consistent with the regulatory momentum created by resmetirom’s approval and the advancing Phase III incretin programmes. The convergence of GLP-1-based therapies on the MASH indication — from selective GLP-1R agonists to dual GIP/GLP-1 agonists to combination regimens — represents a paradigm shift in hepatology that is being actively shaped by both clinical data and IP strategy in parallel.